Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F.
Mollica V, et al. Among authors: maggio i.
Expert Rev Anticancer Ther. 2020 Sep;20(9):755-763. doi: 10.1080/14737140.2020.1807334. Epub 2020 Aug 16.
Expert Rev Anticancer Ther. 2020.
PMID: 32757789
Review.